EWA
GYRE icon

EverSource Wealth Advisors’s Gyre Therapeutics GYRE Stock Holding History

EverSource Wealth Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133 Buy
20
+17
+567% +$116 ﹤0.01% 4281
2026
Q1 		$21 Buy
+3
New +$23 ﹤0.01% 4356
2025
Q2 		– Sell
-22
Closed -$170 – 4294
2025
Q1 		$170 Buy
+22
New +$241 ﹤0.01% 3730

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EverSource Wealth Advisors's GYRE Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Gyre Therapeutics (GYRE) stake by 567% in Q2 2026, buying an estimated $116 and bringing the position to 20 shares worth $133. The position accounts for ﹤0.01% of the portfolio, ranked #4281.

EverSource Wealth Advisors first reported a position in GYRE in Q1 2025 and has held it in 3 quarters since. The position peaked at $170 in Q1 2025. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • EverSource Wealth Advisors held 20 shares of Gyre Therapeutics worth $133 as of Q2 2026.
  • EverSource Wealth Advisors bought 17 Gyre Therapeutics shares in Q2 2026, an estimated $116.
  • Gyre Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4281 holding.
  • EverSource Wealth Advisors first reported a position in Gyre Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • EverSource Wealth Advisors's Gyre Therapeutics position peaked at $170 in Q1 2025.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.